Correlogic Systems’ “Hidden Patterns” Awarded U.S. Patent Protection 

Novel approach to disease detection and other applications covered under broad approval

BETHESDA, MD – August 15, 2005 -- Correlogic Systems, Inc. today announced that the invention, A Process for Distinguishing between Biological States Based on Hidden Patterns from Biological Data (“Hidden Patterns”) has been awarded U.S. Patent No. 6,925,389 by the U.S. Patent and Trademark Office.  The patent is based on the concept that subtle patterns of changes occurring in the body, including those reflected in serum, urine, and secretions such as saliva and perspiration, can be used to identify disease and other biological conditions. 

Correlogic’s pattern recognition approach can be used as a highly effective means of identifying the presence of certain types of cancer and other diseases, as well as monitoring drug toxicity and efficacy.  In addition to medical applications, the patent also covers the wide range of other biological “Hidden Patterns” applications. 

“We believe that hidden pattern recognition will play an important role in diagnostic testing, and we are pleased that Correlogic has been granted this patent,” said Surya N. Mohapatra, Ph.D., Chairman and CEO of Quest Diagnostics Incorporated (NYSE: DGX), which retains an option to commercialize specified diagnostic tests Correlogic is currently developing for certain disease states. 

Correlogic’s first application of “Hidden Patterns” has been to the early detection of disease including ovarian, prostate, and pancreatic cancers.  “Hidden Patterns” has also been used successfully to distinguish recurrence/remission of Wegener’s disease, and has been used in drug toxicity and other non-disease applications.  Correlogic’s research on biological applications of “Hidden Patterns” has been published in peer-reviewed scientific journals, including The Lancet, Journal of the National Cancer Institute, Endocrine-Related Cancer, Journal of Urology, Arthritis and Rheumatism, Cancer Cell, Toxicologic Pathology, and Analytical Chemistry. 

“’Hidden Patterns’ has the potential to transform disease detection, enabling it to be earlier and more accurate, less invasive and less costly,” said Peter J. Levine, president and CEO of Correlogic Systems, Inc.  “Correlogic is moving quickly to take the technology from the research lab into the hands of health care providers.”

The patent is co-owned by Correlogic and the Public Health Service which has licensed its commercialization rights exclusively to Correlogic.

About Correlogic Systems, Inc.

Correlogic Systems, Inc. is a Bethesda, Maryland-based clinical proteomics company that has developed proprietary technology and processes with a wide variety of applications for biomarker discovery, disease detection, and new drug discovery.  The technology’s first application has been in the field of proteomics – the study of human proteins.  OvaCheck^®, a blood test for the early detection of ovarian cancer, is Correlogic’s first diagnostic test using “Hidden Patterns”.  The test is undergoing the final stages of its extensive validation process.  Correlogic has entered into licensing agreements with Quest Diagnostics, Inc., and Laboratory Corporation of America for the North American market development and commercialization of OvaCheck.

Correlogic is also conducting research on the application of “Hidden Patterns” to breast and colon cancer.  Visit Correlogic Systems at www.correlogic.com.

Cautionary Statement:

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances.  Actual results could differ materially due to, among other things, operational and other difficulties associated with integrating acquired business, general business conditions, competition among managed care companies, rising health costs, trends in medical loss ratios, health care reform, delay in receipt of regulatory and other approvals for pending transactions and other regulatory issues.